reason report
extens applic narrow zolgensma ip scenario pt
bottom line review patent extens applic file
uspto compani look delay expiri key
patent cover zolgensma impli us
zolgensma royalti like discontinu file reduc
uncertainti surround durat zolgensma royalti stream
narrow rang potenti return profil share
take blue-ski grey-ski case expiri
respect larg tabl line recent move
sidelin see impli patent life modestli shorter
previou assumpt expiri assum world-wide ip follow
similar expiri timelin us give full credit extens term
adjust model expiri lower pt maintain
patent extens would prolong zolgensma ip march
file extens patent adeno-associ
use therefor sourc
http //portal uspto gov/pair/publicpair email us copi
applic patent contain claim zolgensma method
use product specif cover use capsid
gene therapi vector seek patent extens day
would extend patent life patent
extend one half number day ind nda file
plu full number day nda file approv
maximum year patent last-to-expir us ip
protect zolgensma identifi impli us zolgensma royalti
termin model purpos assum world-wide
ip follow similar expiri timelin
chang model assum zolgensma previous
royalti stream end vs prior
zolgensma royalti estim decreas move
pt
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep dilut
pleas refer page import disclosur price chart analyst certif
rate share market perform see headlin risk nvs/avx preclin
data manipul scandal broadli appreci investor remain optimist
zolgensma blockbust see current valuat adequ account robust
royalti stream zolgensma partner asset well compani wholli
own pipelin see crowd competit landscap challeng clinic practic
wet unclear commerci potenti
mucopolysaccharidos type ii mp mp ii clinic meaning data
homozyg famili hypercholesterolemia hofh yet disclos though see
robust clinic scientif rational program cautious optimist
futur data would justifi valu ascrib asset addit compani strong
cash posit potenti non-dilut capit ip licens posit limit balanc
sheet risk due mix risk/reward profil share across program near-
mid-term catalyst consid collect find difficult compellingli argu investor
deploy fresh capit either long short basi present
price target base dcf methodolog forecast risk-
adjust sale risk-adjust royalti
key partner program explicitli model expens result cash flow
assum discount rate consist clinic stage pre-revenu compani
coverag univers termin growth rate addit includ rgnx net cash
balanc valuat
risk view outlook valuat inc includ major chang
price reimburs coverag gene therapi agent unexpect safeti efficaci
signal clinic develop chang regulatori environ forecast subject
unmodel competitor entrant includ gene edit disrupt technolog
could potenti compet share aav-bas therapi develop partner
convers sale royalti forecast includ estim impact certain competit
agent agent fail enter market poorer-than-expect clinic profil
otherwis fail garner share expect could repres materi upsid
estim element compani busi model depend monet
core ip asset chang intellectu properti law enforc compani ip
portfolio could materi impact compani prospect futur cash flow
total cost revenu
research develop
gener administr
sale market
loss incom oper
interest incom licens
total incom expens
loss incom tax
compani report svb leerink equiti research estim
bs mm
cash equival
properti equip net
accru expens current liabil
defer rent net current portion
accumul comprehens loss incom
total liabil stockhold equiti
compani report svb leerink equiti research estim
chang
oper
net amort premium accret discount market debt secur
invest
financ
proce exercis stock option
compani report svb leerink equiti research estim
scenario risdiplam succe type ii/iii sma
scenario risdiplam fail type ii/iii sma
royalti
ww royalties/profit share p/w
total p/w royalti
compani report svb leerink equiti research estim
brand
type event
event trial detail
expect
submiss ind form batten
svb leerink llc equiti research compani file
